NCT03023423View on ClinicalTrials.gov

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

December 23, 2016

Primary Completion Date

May 17, 2018

Study Completion Date

September 26, 2019

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Atezolizumab

Participants will receive atezolizumab 1200 mg intravenously.

DRUG

Daratumumab

Participants will receive daratumumab 16 mg/kg intravenously.

Trial Locations (47)

Unknown

Loma Linda

Whittier

Newark

Deerfield Beach

Fort Lauderdale

Orlando

Tampa

Athens

Atlanta

New Orleans

Bethesda

Oklahoma City

Chattanooga

Knoxville

Nashville

Spokane

Bordeaux

Boulogne-Billancourt

Caen

Créteil

Haut-Rhin

Montpellier

Nancy

Paris

Rennes

Rouen

Suresnes

Vandœuvre-lès-Nancy

Budapest

Székesfehérvár

Tatabánya

Lodz

Otwock

Wieliszew

Barcelona

Elche

Jaén

Leganés

Madrid

Málaga

Murcia

Palma de Mallorca

Pozuelo de Alarcón

San Sebastián

Sótano

Valencia

Zaragoza

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03023423 - A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter